Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05234177 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With CRC Using NGS Assays

StatusRecruiting
PhaseNot specified
SponsorTempus AI
Started
View on ClinicalTrials.gov ↗

Record History

  1. Site contacts updated at 1 of 20 sitesv16
  2. Site contacts updated at 20 of 20 sitesv15
  3. Enrollment target: 160 to 300 Primary completion date: Feb 2025 to Feb 2027 · Completion date: Feb 2027 to Feb 2029 · Eligibility criteria revised · 1 morev14 Show 4 more changesShow less
    • Primary completion date: Feb 2025 to Feb 2027
    • Completion date: Feb 2027 to Feb 2029
    • Eligibility criteria revised
    • Site contacts updated at 2 of 20 sites

    See this version in full on ClinicalTrials.gov ↗

  4. Re-verified, no change to tracked fieldsv13
  5. Site contacts updated at 20 of 20 sitesv12
Show 10 earlier versionsHide 10 earlier versions
  1. 4 versions Re-verified since Apr 2, 2024, no change to tracked fieldsv8-v11
  2. Primary completion date: Feb 2024 to Feb 2025v7
  3. Study sites: 13 to 20v6
  4. Re-verified, no change to tracked fieldsv5
  5. Study sites: 4 to 13v4
  6. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 4 · Start date changed from estimate of May 2022 to Jun 21, 2022v3 Show 2 more changesShow less
    • Study sites: 0 to 4
    • Start date changed from estimate of May 2022 to Jun 21, 2022
  7. Start date: Feb 2022 to May 2022v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Tempus AI
13 trials monitored
See all monitored trials
Colorectal Cancer
2,920 trials monitored
See 132 trials at risk
The study is an observational multicenter evaluation of participants with colorectal cancer (CRC) who will receive longitudinal plasma ctDNA biomarker profiling in addition to their standard-of-care therapy and disease surveillance.
Trial Details
NCT Number NCT05234177
Lead Sponsor Tempus AI
Conditions Colorectal Cancer
Enrollment 300 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov